ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Werewolf Therapeutics Inc

Werewolf Therapeutics Inc (HOWL)

6.35
0.00
( 0.00% )
Updated: 11:28:06

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
6.35
Bid
6.34
Ask
6.39
Volume
115,130
6.24 Day's Range 6.66
1.5735 52 Week Range 8.1939
Market Cap
Previous Close
6.35
Open
6.43
Last Trade
5
@
6.355
Last Trade Time
11:32:07
Financial Volume
$ 749,960
VWAP
6.514
Average Volume (3m)
258,673
Shares Outstanding
42,737,191
Dividend Yield
-
PE Ratio
-7.32
Earnings Per Share (EPS)
-0.87
Revenue
19.94M
Net Profit
-37.37M

About Werewolf Therapeutics Inc

Werewolf Therapeutics Inc is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. Werewolf Therapeutics Inc is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Werewolf Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker HOWL. The last closing price for Werewolf Therapeutics was $6.35. Over the last year, Werewolf Therapeutics shares have traded in a share price range of $ 1.5735 to $ 8.1939.

Werewolf Therapeutics currently has 42,737,191 shares outstanding. The market capitalization of Werewolf Therapeutics is $273.52 million. Werewolf Therapeutics has a price to earnings ratio (PE ratio) of -7.32.

HOWL Latest News

Form S-8 - Securities to be offered to employees in employee benefit plans

As filed with the Securities and Exchange Commission on March 7, 2024Registration No. 333-__________   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

00017855302023FYFALSE00017855302023-01-012023-12-3100017855302023-06-30iso4217:USD00017855302024-03-01xbrli:shares00017855302023-10-012023-12-3100017855302023-12-3100017855302022-12-31iso4217:USDxb...

Form 8-K - Current report

0001785530FALSE00017855302024-03-072024-03-07UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549______________________FORM 8-K______________________CURRENT REPORTPursuant to...

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

–  Additional monotherapy dose-escalation data from ongoing Phase 1/1b clinical trial of WTX-124 expected to be presented in the first half of 2024  – –  WTX-124 recommended dose for expansion...

Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference

WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development...

Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024

WATERTOWN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development...

Form 8-K - Current report

false 0001785530 0001785530 2024-02-09 2024-02-09     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Table of Contents Filed Pursuant to Rule 424(b)(5)Registration No. 333-264844 PROSPECTUS SUPPLEMENT (To Prospectus dated May 20, 2022)     Up to $25,000,000 Common Stock...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.182.917341977316.176.735.771436836.0740092CS
4-0.06-0.9360374414986.417.3055.771752706.36072585CS
121.9644.64692482924.398.19393.862586735.66182571CS
264.12184.7533632292.238.19391.57355935683.56748992CS
523.99169.067796612.368.19391.57353177043.52479915CS
156-11.86-65.129049972518.2123.991.392202515.28466588CS
260-11.86-65.129049972518.2123.991.392202515.28466588CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 23.5501
(395.79%)
17.33M
XLOXilio Therapeutics Inc
$ 1.675
(162.13%)
24.24M
BDRXBiodexa Pharmaceuticals PLC
$ 1.61
(87.43%)
70.07M
CEROCERo Therapeutics Holdings Inc
$ 2.31
(41.72%)
1.46M
PIKKidpik Corporation
$ 4.62
(41.28%)
8.38M
PMECPrimech Holdings Ltd
$ 1.805
(-53.48%)
2.99M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
GMDAGamida Cell Ltd
$ 0.0417
(-29.56%)
43.03M
DTSTData Storage Corporation
$ 5.7255
(-25.06%)
535.2k
UGROUrban Gro Inc
$ 1.3606
(-25.04%)
357.02k
NKLANikola Corporation
$ 1.02
(12.20%)
100.87M
BDRXBiodexa Pharmaceuticals PLC
$ 1.61
(87.43%)
70.07M
AKANAkanda Corporation
$ 0.192
(16.43%)
55.58M
MARAMarathon Digital Holdings Inc
$ 23.72
(7.48%)
44.49M
GMDAGamida Cell Ltd
$ 0.0417
(-29.56%)
43.03M

HOWL Discussion

View Posts
Monksdream Monksdream 3 months ago
HOWL new 52 week high
👍️0
Pt3 Pt3 5 months ago
Yea your gap and trapped make me buy caud instead of this
👍️0
TheFinalCD TheFinalCD 5 months ago
HOWL todays algo patented Gap & Trap on Phase #1 news
👍️0
TheFinalCD TheFinalCD 5 months ago
Werewolf Therapeutics soars 52% premarket after presentsing preliminary monotherapy data from Phase 1/1b clinical trial establishing proof of mechanism for WTX-124$HOWL#AInvest #Ainvest_Wire #trade #source #wallstreet
View more: https://t.co/aTzfU7GqUS pic.twitter.com/rClSWzl2IS— AInvest Wire (@Ainvest_Wire) November 3, 2023
👍️0
TheFinalCD TheFinalCD 5 months ago
$howl flying https://finviz.com/quote.ashx?t=HOWL&ty=c&ta=1&p=d

https://dilutiontracker.com/app/search/HOWL
👍️0
tw0122 tw0122 5 months ago
$3 + otw Halloween is here give it a HOWL
👍️0
The Night Stalker The Night Stalker 9 months ago
https://stockcharts.com/h-sc/ui?s=howl&p=W&yr=0&mn=11&dy=25&id=p34307943936&a=1105106922&listNum=2
👍️0
The Night Stalker The Night Stalker 9 months ago
https://stockcharts.com/h-sc/ui?s=howl&p=W&yr=0&mn=11&dy=25&id=p34307943936&a=1105106922&listNum=2
👍️0
The Night Stalker The Night Stalker 9 months ago
dip
👍️0
The Night Stalker The Night Stalker 9 months ago
dip
👍️0
The Night Stalker The Night Stalker 9 months ago
watching
👍️0
The Night Stalker The Night Stalker 10 months ago
soon
👍️0
The Night Stalker The Night Stalker 10 months ago
insert dd
👍️0
The Night Stalker The Night Stalker 10 months ago
can be big
👍️0
The Night Stalker The Night Stalker 10 months ago
wow
👍️0
The Night Stalker The Night Stalker 10 months ago
wow
👍️0
The Night Stalker The Night Stalker 10 months ago
hold
👍️0
The Night Stalker The Night Stalker 10 months ago
slow
👍️0
The Night Stalker The Night Stalker 10 months ago
slow
👍️0
The Night Stalker The Night Stalker 10 months ago
agreed
👍️0
The Night Stalker The Night Stalker 10 months ago
like thiks
👍️0
The Night Stalker The Night Stalker 10 months ago
off radar
👍️0
The Night Stalker The Night Stalker 10 months ago
catchy name
👍️0
The Night Stalker The Night Stalker 10 months ago
catchy name
👍️0
surf1944 surf1944 11 months ago
https://stockcharts.com/h-sc/ui?s=howl&p=D&yr=0&mn=6&dy=0&id=p38090673899

https://www.barchart.com/stocks/quotes/howl/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=SYSX&grid=1&height=210&studyheight=100

https://www.barchart.com/stocks/quotes/howl/opinion
👍️0
Mr. Zen Mr. Zen 1 year ago
Watch list addition, this has the potential to run, just waiting for all the pieces of the puzzle to come together.

“These promising preclinical data add to a growing body of evidence demonstrating the potential of WTX-330 to drive targeted anti-tumor immune responses selectively in the tumor microenvironment (TME),” said Cynthia Seidel-Dugan, Ph.D., Chief Scientific Officer of Werewolf Therapeutics. “This morning, in our Third Quarter 2022 release, we announced that the FDA has granted clearance of the investigational new drug (IND) application for WTX-330. We are excited to advance WTX-330 into the clinic and to continue developing a pipeline of novel proinflammatory cytokine therapies that have the potential to change the lives of cancer patients.”
👍️0
makinezmoney makinezmoney 1 year ago
$HOWL: Hey thanks....... now 3.20.

Only getting better right ??


Enjoy those profits.





GO $HOWL
👍️0
Makk1 Makk1 1 year ago
Good call here, looking very good
👍️0
makinezmoney makinezmoney 1 year ago
$HOWL: Looks like its turning...... now 2.25

Let see if volume pushes it up.


The setup is nice


GO $HOWL
👍️0
bobbo5 bobbo5 1 year ago
I agree and it looks like share price has been moving up this past week
👍️0
dia76ca dia76ca 1 year ago
Very interesting company. I like it's chances.
👍️0

Your Recent History

Delayed Upgrade Clock